Blocking HDAC6 to protect kidneys during cisplatin chemotherapy
Official title: Save Kidneys in Cisplatin Chemotherapy by blocking HDAC6
Funded at Rhode Island Hospital · NIH-11404842 · Data updated 2026-11-12
Aimed at preventing kidney injury from cisplatin cancer treatment by blocking HDAC6, with the hope of keeping kidneys healthy during chemotherapy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rhode Island Hospital NIH-funded |
| Lab location | 1 site (Providence, United States) |
| Project start | September 8, 2025 |
| Project end | May 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $643,182 |
| NIH project number | 5R01DK142969-02 |
| Project ID | NIH-11404842 on NIH RePORTER |
Who could benefit from this research
✓Could help
Not applicable at this stage; preclinical research using animal and cell models.
✕Less likely to help
No direct patient treatment is involved in this early-stage study.
What this research studies
This project looks at how blocking HDAC6 could shield the kidneys from damage caused by cisplatin, a common cancer drug. Researchers will study how HDAC6 affects kidney cells during treatment and whether blocking it reduces cell death and scarring. The work relies on animal studies and cellular models to understand the mechanism and test potential protective strategies. If successful, this approach could lead to a new way to reduce kidney injury in patients receiving cisplatin.
Why it matters
Potential benefit: If HDAC6 blockade protects kidneys, patients could receive effective cancer treatment with less risk of kidney injury.
How similar studies have gone: Preclinical data suggest HDAC6 inhibition reduces kidney injury and fibrosis in response to cisplatin in models.
Where this research is happening
-
Rhode Island Hospital
Providence, United States Active
Researchers
- Principal investigator: Zhuang, Shougang — Rhode Island Hospital
- Study coordinator: Zhuang, Shougang
Related research
Other NIH-funded projects on the same topics.
-
Photodynamic lipids to boost chemotherapy for metastatic ovarian cancer
A patient-friendly approach tests a light-activated method to make ovarian cancer metastases more sensitive to chemotherapy.
-
Dual targeting of heart cell receptors to prevent chemotherapy heart damage
Atrial patients receiving the chemotherapy drug doxorubicin may be protected from heart damage by targeting two heart cell receptors at once.
-
A 3D ultrasound scanner to see early chemotherapy response in breast cancer
A new 3D ultrasound imaging method will be tested to see if it can quickly show whether breast cancer is responding to chemotherapy.
-
Non-invasive, microscopic biomarkers to detect CIPN in chemotherapy patients
This grant aims to develop a non-invasive imaging method to measure nerve changes in patients undergoing chemotherapy to better understand and monitor chemotherapy-induced peripheral neuropathy (CIPN).
-
Alternative NF-kB activation after chemotherapy in ovarian cancer
This grant studies how ovarian cancer might come back after chemotherapy by looking at specific signaling pathways in cancer cells and the tumor environment.
-
Genetic clues for doxorubicin heart risk using patient-derived heart cells
A research project tests how human heart cells grown from stem cells react to a common chemotherapy to see which genetic differences may raise the risk of heart damage.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.